Abstract The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil
are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil …

Phosphodiesterase type-5 (PDE5) inhibitors are widely used as first-line therapy for erectile
dysfunction (ED). Their efficacy and safety combined with an increasing understanding of …

The introduction of oral agents for the treatment of erectile dysfunction (ED) has
revolutionized the treatment of men with erection problems of all severities and etiologies …

Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding
nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely …

The discovery of the nitric oxide/cGMP pathway was the basis for our understanding of many
normal physiological functions and the pathophysiology of several diseases. Since the …

PDE-5 inhibitors were originally studied in cardiovascular indications but were later
developed and approved for on-demand treatment of erectile dysfunction (ED). A few years …

Importance to the field: Since sildenafil was introduced 10 years ago, highly selective
phosphodiesterase type 5 inhibitors (PDE5i) have changed the medical management of …

Since the discovery of sildenafil in 1989 as a highly selective inhibitor of the
phosphodiesterase type-5 (PDE-5) receptor, 2 additional PDE-5 inhibitors, tadalafil and …

This is our first presentation of Great Drug Classes, and we start with a description of
phosphodiesterase type 5 inhibitors and their use in erectile dysfunction. This is an in‐depth …

PDE5 inhibitors have been clearly established as first-line therapy for the treatment of
erectile dysfunction (ED). Three PDE5 inhibitors-sildenafil (Viagra®), vardenafil (Levitra®) …